Bio-Matrix Scientific Group Inc. announced today its subsidiary Regen BioPharma Inc. signed an agreement with Dr. Wei-Ping Min covering experiments requested by the FDA in support of clearance for the company's IND #15376 for use of HemaXellerate I in the treatment of drug refractory aplastic anemia.
http://www.biospace.com/news_story.aspx?StoryID=309884&full=1
http://www.biospace.com/news_story.aspx?StoryID=309884&full=1
No comments:
Post a Comment